Sulfamethoxazole-trimethoprim for infections in cancer patients
W. E. Grose, G. P. Bodey and V. Rodriguez
A combination of sulfamethoxazole and trimethoprim (Bactrim) was given
orally to 35 cancer pattients with infections. Thirty-two patients did not
respond to an initial antibiotic regimen that consisted primarily of
carbenicillin disodium and an aminoglycoside. There were 18
single-organism, Gram-negative infections. The overall cure rate was 54%.
The most common infection was pneumonia (47% responded to treatment).
Eighty precent of the cases of septicemia were cured. The most common
infecting organism was Klebsiella pneumoniae (45% with this infection
responded). Eight cases of infection of unknown origin occurred (63%
responded to treatment). Overall, 47% of the patients whose neutrophil
count remained unchanged or decreased responded, while 61% of those whose
neutrophil count remained unchanged or increased responded. There was no
close correlation between the minimum inhibitory concentrations and the
clinical responses. Sulfamethoxazole-trimethoprim orally is a well
tolerated and effective form of antimicrobial therapy.